Biogen Inc. (NASDAQ:BIIB) also benefits from its strong pipeline, which shows promise in areas like lupus and Alzheimer’s ...
Biogen downgraded to Hold by Needham amid projected flat revenues until 2026. Leqembi and other new product sales show ...
Worldcrunch on MSN1d
Leqembi, Is This New Drug The Turning Point In Curing Alzheimer’s?Lecanemab, marketed as Leqembi, is the first drug targeting the root cause of Alzheimer’s disease to be approved by the ...
Needham has downgraded Biogen (BIIB) to hold from buy, citing a lack of near-term catalysts and slow uptake for the company’s ...
The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...
Reversing an earlier decision, European regulators recommended that the Alzheimer’s therapy Leqembi should be approved ...
Why one trial participant's healthy birth after her CAR-T treatment for lupus is catching resesarchers' attention: ...
Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.
The article provides an overview of recent developments in the healthcare sector, including Novo Nordisk's phase-out of ...
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
The EMA has changed its mind about an earlier decision that the risks of Leqembi (lecanemab) outweigh the benefits and is now recommending the Alzheimer’s disease drug is approved for a subgroup of ...
Researchers at Texas A&M University have developed a nasal spray shown to delay disease progression in animals -- fueling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback